A Study on Attitude of Indian Citizen towards Covid – 19 Vaccinations

M. RAGHURAM B.Com, MBA., DR. J. RANI MBA, M.Phil., Ph. D

School of Management studies, Sathyabama Institute of science and technology Chennai, Tamil Nadu, South India

Assistant Professor, Sathyabama Institute of science and technology Chennai, Tamil Nadu, South India

Submitted: 15-04-2022 Revised: 27-04-2022 Accepted: 30-04-2022

ABSTRACT

Vaccines are effective interventions that can reduce the high burden of diseases globally. However, public vaccine hesitancy is a pressing problem for public health authorities, With the availability of COVID-19 vaccines, little information is available on the public acceptability and attitudes towards the COVID-19 vaccines. This study aimed to investigate the acceptability of COVID-19 vaccines and its predictors in addition to the attitudes towards these vaccines among public.

I. INTRODUCTION

The pandemic has disrupted the life of people globally. Amidst this grim situation, one of the positive signs of human resilience is the development of effective and safe vaccines, within a year of onset of the pandemic. Vaccines are effective public health tools, which when given to sufficient numbers of people, can halt outbreaks of serious infections. The world currently faces a gross inequity in access to COVID-19 vaccines. While high income countries are making great strides in giving vaccines to all its people, low and middle income countries are still languishing with poor vaccine access.

II. REVIEW OF LITERATURE

- ABURTO JM, Solly J, ahis sky I, et al.

INDUSTRY PROFILE

To ensure the latest information is available, the landscape will be updated twice a week by searching, gathering and cross-checking data from multiple sources such as the Cochrane vaccine mapping tool, PubMed, Clinical Trials gov, WHOICTRP and from a network of researchers and industry for new candidate vaccines by screening registered trials for clinical information. Where data is missing, we either do not add any information or we supplement information gathered from press or public releases. We welcome your feedback to help us update or make necessary changes.

OBJECTIVES

Rapid deployment of vaccines against COVID-19 may enable non-pharmaceutical interventions to be eased in the coming months. Efficient and effective vaccination strategies should be directed by explicit objectives.

NEED FOR THE STUDY

A COVID Vaccine Certificate (CVC) issued by the government offers an assurance to the beneficiary on the vaccination, type of vaccine used, and the provisional certificate also provides the next vaccination due. It is also evidence for the citizen to prove to any entities which may require proof of vaccination specially in case of travel.
SCOPE OF THE STUDY
Acceptance of vaccines has been on the decline in recent years. Despite encouraging early results for coronavirus vaccine trials, achieving herd immunity requires substantial uptake. We presented scenarios varying vaccine efficacy, minor side effects, and severe reactions to a sample representative of the US population.

RESEARCH METHODOLOGY
Vaccines go through various phases of development and testing—there are usually three phases to clinical trials, with the last one designed to assess the ability of the product to protect against disease, which is called efficacy. All phases assess safety.

SOURCES OF DATA:
Primary data- Questionnaire given with 66 respondents. Secondary data- Websites and online journals, Published reports and review of literature from published article.

STRUCTURE OF QUESTIONNAIRE:
Questionnaire was divided into two sections.
First part was designed to know general information about respondents and the second part contained the respondent opinion about Indian Citizen’s.
Basic introduction
Personal details
Research related question
Perception questions
Likert scaling Questions
Suggestion questions

III. DATA ANALYSIS

TABLE 1: AGE OF THE RESPONSE

<table>
<thead>
<tr>
<th>PARTICULAR</th>
<th>NO OF RESPONSE</th>
<th>PERCENTAGE OF RESPONSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>18-22</td>
<td>40</td>
<td>60.6</td>
</tr>
<tr>
<td>22-30</td>
<td>18</td>
<td>27.3</td>
</tr>
<tr>
<td>30-45</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>45 and above</td>
<td>2</td>
<td>3.1</td>
</tr>
</tbody>
</table>

INTREPRETATION
From the above table shows that the age of the response 60.6% of 18-22, 27.3% of 22-30, 9% of 30-45, and 3.1% of 45 and above of the respondent.

TABLE 4: WHAT ARE THE SYMPTOMS FACED AFTER GETTING VACCINATED?

<table>
<thead>
<tr>
<th>PARTICULAR</th>
<th>NO OF RESPONSE</th>
<th>PERCENTAGE OF RESPONSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>COLD</td>
<td>1</td>
<td>1.5</td>
</tr>
<tr>
<td>COUGH</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>HEADACHE</td>
<td>4</td>
<td>6.1</td>
</tr>
<tr>
<td>FEVER</td>
<td>9</td>
<td>13.6</td>
</tr>
<tr>
<td>BOTH A AND B</td>
<td>33</td>
<td>50</td>
</tr>
<tr>
<td>ACHES AND FEVER</td>
<td>10</td>
<td>15.2</td>
</tr>
<tr>
<td>FATIGUE AND HEADACHE</td>
<td>9</td>
<td>13.6</td>
</tr>
</tbody>
</table>

INTREPRETATION
From the above shows that the what are the symptoms faced after getting vaccinated of the response 1.5% of cold, 0% of cough, 6.1% of headache, 13.6% of fever, 50% of both a and b, 15.2% of aches and fever and 13.6% of fatigue and headache.
IV. CONCLUSIONS

The coronavirus disease continues to spread across the world following a trajectory that is difficult to predict. The health, humanitarian and socioeconomic policies adopted by countries will determine the speed and strength of the recovery.

REFERENCE

[1]. Journals.plos.org
[3]. docs.google.com
[4]. www.who.int
[5]. www.cidrap.unm.edu
[6]. www.mintegral.com
[7]. www.mdpi.com
[8]. www.axiomllc.com